Access a unique set of tools and technologies

Cellectis licenses out proprietary technologies providing:

• access to available engineered meganucleases;
• access to Cellectis’ meganuclease engineering platform in the context of partnerships for developing new therapy-focused programs, cell lines, or agricultural biotechnology;
• access to gene replacement and homologous recombination patents, in order to create and use transgenic cells and animals.

For licensing opportunities, please contact Cellectis’ business development team.